China Rights To Isotechnika Pharma Inc.'s Transplant Drug Sold To 3SBio Inc. For US$6 Million

TORONTO, Aug 24 (Reuters) - Isotechnika Pharma Inc (ISA.TO) shares rose more than 40 percent on Tuesday after it announced a partnership with China’s 3SBio Inc (SSRX.O) to develop and commercialize an autoimmune and transplant drug.

MORE ON THIS TOPIC